TARS:NSD-Tarsus Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 32.12

Change

+0.08 (+0.25)%

Market Cap

USD 1.22B

Volume

0.45M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+3.15 (+0.72%)

USD 109.10B
REGN Regeneron Pharmaceuticals Inc

-10.23 (-1.05%)

USD 107.30B
MRNA Moderna Inc

+3.62 (+2.80%)

USD 44.96B
ARGX argenx NV ADR

-0.36 (-0.10%)

USD 22.43B
BNTX BioNTech SE

+0.78 (+0.85%)

USD 22.34B
ALNY Alnylam Pharmaceuticals Inc

+3.82 (+2.59%)

USD 18.64B
BGNE BeiGene Ltd

+6.15 (+3.73%)

USD 18.28B
GMAB Genmab AS

-0.57 (-1.89%)

USD 18.26B
BMRN Biomarin Pharmaceutical Inc

-3.43 (-4.27%)

USD 15.29B
TECH Bio-Techne Corp

-0.66 (-0.79%)

USD 13.26B

ETFs Containing TARS

BBP Virtus LifeSci Biotech Pr.. 3.86 % 0.79 %

-0.16 (-0.74%)

USD 0.02B
XMHQ Invesco S&P MidCap Qualit.. 2.63 % 0.25 %

-1.18 (-0.74%)

USD 5.03B
PAMC Pacer Lunt MidCap Multi-F.. 2.23 % 0.00 %

-0.59 (-0.74%)

USD 0.06B
AFMC First Trust Active Factor.. 1.28 % 0.00 %

-0.34 (-0.74%)

USD 7.48M
IVOG Vanguard S&P Mid-Cap 400 .. 1.21 % 0.20 %

-1.20 (-0.74%)

USD 1.02B
IJK iShares S&P Mid-Cap 400 G.. 1.20 % 0.24 %

-0.96 (-0.74%)

USD 9.59B
DEUS Xtrackers Russell US Mult.. 0.72 % 0.18 %

-0.10 (-0.74%)

USD 0.15B
MDY SPDR® S&P MIDCAP 400 ETF.. 0.71 % 0.24 %

-5.06 (-0.74%)

USD 21.64B
ZMID:CA BMO S&P US Mid Cap Index .. 0.70 % 0.00 %

-0.19 (-0.74%)

N/A
ZMID-F:CA BMO S&P US Mid Cap Index .. 0.70 % 0.00 %

N/A

CAD 2.03M
ZMID-U:CA BMO S&P US Mid Cap Index .. 0.70 % 0.00 %

N/A

N/A
QVMM Invesco Exchange-Traded F.. 0.69 % 0.00 %

-0.21 (-0.74%)

USD 0.31B
SPY4:LSE SSgA SPDR ETFs Europe I P.. 0.63 % 0.00 %

-0.24 (-0.74%)

USD 1.90B
SPY4:PA SSgA SPDR S&P 400 US Mid .. 0.63 % 0.00 %

-0.20 (-0.74%)

USD 1.99B
SPY4:F SSgA SPDR S&P 400 US Mid .. 0.63 % 0.00 %

-0.34 (-0.74%)

USD 1.99B
SPY4:XETRA SSgA SPDR S&P 400 US Mid .. 0.63 % 0.00 %

-0.24 (-0.74%)

USD 1.99B
IVOO Vanguard S&P Mid-Cap 400 .. 0.63 % 0.15 %

-0.82 (-0.74%)

USD 2.01B
IJH iShares Core S&P Mid-Cap .. 0.62 % 0.07 %

-0.53 (-0.74%)

USD 84.01B
BKMC BNY Mellon US Mid Cap Cor.. 0.56 % 0.00 %

-0.68 (-0.74%)

USD 0.47B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 58.62% 87% B+ 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.62% 87% B+ 92% A
Trailing 12 Months  
Capital Gain 111.04% 92% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 111.04% 92% A 95% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.20% 57% F 43% F
Dividend Return -1.20% 57% F 38% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.42% 59% D- 35% F
Risk Adjusted Return -2.53% 56% F 40% F
Market Capitalization 1.22B 85% B 75% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector